BioLineRx Ltd. (BLRX) Stock Forecast
BLRX analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 1 analysts
- Price target
- $22.00 average of analyst targets
- Upside to target
- +994.5% from the latest close
- Next earnings
- November 23, 2026 EPS estimate $-0.38
- 52-week range
- $2.01 – $3.78
BLRX analyst ratings
1 analystsNumber of analysts at each rating.
BLRX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
BLRX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.77 | −$0.77 | −$0.77 | $0.00 | 0.0% | 1 |
| Current fiscal year (2026) | −$3.14 | −$3.14 | −$3.14 | $0.00 | 0.0% | 1 |
| Next fiscal year (2027) | −$2.52 | −$2.52 | −$2.52 | −$3.14 | +19.8% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
BLRX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $357,500 | $340,000 | $375,000 | −16.3% | 2 |
| Current fiscal year (2026) | $1.6M | $1.5M | $1.7M | +37.3% | 2 |
| Next fiscal year (2027) | $2.2M | $1.9M | $2.5M | +37.1% | 2 |
BLRX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
BLRX revenue: reported and forecast
BLRX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.18 | −$0.18 | $0.00 | $0.00 | −$0.77 | +327.8% | 1 up · 0 down |
| Current fiscal year (2026) | −$0.93 | −$0.93 | $0.00 | $0.00 | −$3.14 | +237.6% | 1 up · 0 down |
| Next fiscal year (2027) | −$0.64 | −$0.64 | $0.00 | $0.00 | −$2.52 | +293.8% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
BLRX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; BLRX beat in 8 of 12.
What analysts expect from BLRX
1 analysts cover BioLineRx; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $22.00, 994.5% above the latest close of $2.01. Analysts expect earnings of −$3.14 per share for 2026, 0.0% from a year earlier. For 2027 the average estimate is −$2.52 per share on revenue of $2.2 million. BioLineRx beat the EPS estimate in 8 of the last 12 quarters.
Related: BLRX income statement, BLRX key metrics, BLRX chart. See the BLRX stock overview for the latest quote and news.
BLRX forecast FAQ
What is BioLineRx's price target?
The average analyst price target for BioLineRx is $22.00, 994.5% above the latest close of $2.01.
Is BioLineRx a buy, hold or sell?
Of 1 analysts covering BioLineRx, 1 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is BioLineRx's EPS forecast?
Analysts forecast −$3.14 per share for 2026 (range −$3.14 to −$3.14); for 2027 the estimate is −$2.52.
What is BioLineRx's revenue forecast?
The average revenue estimate for 2026 is $1.6 million, growth of 37.3%; for 2027 it is $2.2 million.
When does BioLineRx report earnings?
BioLineRx is expected to report results for the quarter ending September 30, 2026 on November 23, 2026 before the market opens; the EPS estimate is $-0.38.
Does BioLineRx usually beat earnings estimates?
BioLineRx reported EPS at or above the analyst estimate in 8 of the last 12 quarters.